Personalised clinical decision support for diabetes management using real-time data.
Clare Martin, Arantza Aldea, Daniel Brown, David Duce, José Manuel Fernández-Real, Pablo Gay, Pantelis Georgiou, R. Harrison, Pau Herrero, Bianca Innocenti, Beatriz López, Yenny Leal, Lucian Nita, Peter Pesl, Roberto Petite, Monika Reddy, Julian Shapley, Ferrant Torrent-Fontbona, Marion Waite, Marzena Wos, Nicholas Oliver.
Advanced Technologies & Treatments for Diabetes.
Paris, France, 2017
Avaluació d'un sistema personalitzat de suport de decisions d'autogestion de la DM1.
Marzena Wos, Yenny Leal, Mercé Fernández-Balsells, Clare Martin, Pau Herrero, Beatriz López, Wifredo Ricart, Lidia Sojo-Vega, Eduardo Esteve, Emilio Loshuertos, Julian Shapley, Lucian Nita, José Manuel Fernández-Real.
XIVè Congrés ACD
Badalona, Spain, 2017
Evaluación de un sistema personalizado de soporte de decisiones de autogestion de la DM1.
Marzena Wos, Yenny Leal, Mercé Fernández Balsells, Clare Martin, Wifredo Ricart, Lidia Sojo Vega, José Manuel Fernández-Real.
XXVIII Congreso Nacional de la Sociedad Española de Diabetes
Barcelona, Spain, 2017
Welcome to the first issue of the Patient Empowerment through Predictive Personalised Decision Support (PEPPER) Project newsletter. This project aims to improve the lives of people with Type 1 diabetes by providing decision support for day-to-day self-management. It is funded by the European Commission's Horizon 2020 Work Programme. In this issue you will find an introduction to the project as well as news of some of the events that have taken place since the launch in February 2016. There are six partners involved, each of which is introduced briefly here. There is also an outline of some of our plans for the future. We hope you enjoy this inaugural issue of our newsletter
It is a great pleasure to welcome you to the second issue of the Patient Empowerment through Predictive Personalised Decision Support (PEPPER) Project newsletter. The project continues to make exciting progress, with Type 1 diabetes patients recruited to the initial feasibility study which is about to start. This issue includes reports of the two most recent project meetings, in Paris and Iasi respectively. The Paris meeting was co-located with the Advanced Technologies and Treatments for Diabetes conference (ATTD 2017), at which we presented an introduction to our work. The project partners have also been busy fostering a network of interested stakeholders. This included organising the Second Workshop on Artificial Intelligence in Diabetes (AID), which took place during the international conference on Artificial Intelligence in Medicine in June, and is described here. I do hope that you enjoy this issue of our newsletter.